Clinical Trial Update: Rh-PDGF vs EMD for Treatment of Intra-bony Defects [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial comparing rh-PDGF to enamel matrix derivative (EMD) for treatment of intrabony periodontal defects; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrabony Periodontal Defect

Drugs mentioned

• EMD (Enamel Matrix Derivative) (enamel matrix derivative)
• rh-PDGF (recombinant human platelet-derived growth factor)

Snippet

Sponsor: Nova Southeastern University | Conditions: Intrabony Periodontal Defect | Phase 1, Phase 2 | Status: RECRUITING